{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:19:37Z","timestamp":1790849977356,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,25]],"date-time":"2016-10-25T00:00:00Z","timestamp":1477353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ijidonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ijid.2016.10.018","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T14:16:50Z","timestamp":1478096210000},"page":"263-267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"special_numbering":"C","title":["Novel approaches to tuberculosis vaccine development"],"prefix":"10.1016","volume":"56","author":[{"given":"Stefan H.E.","family":"Kaufmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"January","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Fordham","family":"von Reyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2016.10.018_bib0220","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/502S2a","article-title":"A mortal foe","volume":"502","author":"Paulson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijid.2016.10.018_bib0225","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/ni1105-1063","article-title":"From bacteriology to immunology: the dualism of specificity","volume":"6","author":"Kaufmann","year":"2005","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijid.2016.10.018_bib0230","series-title":"Global tuberculosis report 2016","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.ijid.2016.10.018_bib0235","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.immuni.2010.09.015","article-title":"Future vaccination strategies against tuberculosis: thinking outside the box","volume":"33","author":"Kaufmann","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.ijid.2016.10.018_bib0240","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.smim.2013.04.006","article-title":"Tuberculosis vaccines: time to think about the next generation","volume":"25","author":"Kaufmann","year":"2013","journal-title":"Semin Immunol"},{"key":"10.1016\/j.ijid.2016.10.018_bib0245","doi-asserted-by":"crossref","first-page":"13980","DOI":"10.1073\/pnas.0901720106","article-title":"Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics","volume":"106","author":"Abu-Raddad","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2016.10.018_bib0250","doi-asserted-by":"crossref","first-page":"e1002607","DOI":"10.1371\/journal.ppat.1002607","article-title":"Vaccines against tuberculosis: where are we and where do we need to go?","volume":"8","author":"Ottenhoff","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2016.10.018_bib0255","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/path.1906","article-title":"New insights into the function of granulomas in human tuberculosis","volume":"208","author":"Ulrichs","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.ijid.2016.10.018_bib0260","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1574-6976.2012.00331.x","article-title":"Mycobacterium tuberculosis: success through dormancy","volume":"36","author":"Gengenbacher","year":"2012","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.ijid.2016.10.018_bib0265","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrmicro2236","article-title":"The spectrum of latent tuberculosis: rethinking the biology and intervention strategies","volume":"7","author":"Barry","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ijid.2016.10.018_bib0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1542\/peds.96.1.29","article-title":"The efficacy of bacillus Calmette\u2013Gu\u00e9rin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature","volume":"96","author":"Colditz","year":"1995","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijid.2016.10.018_bib0275","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1001\/jama.1994.03510330076038","article-title":"Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature","volume":"271","author":"Colditz","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.ijid.2016.10.018_bib0280","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1016\/j.vaccine.2015.05.036","article-title":"The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: a randomized controlled trial","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0285","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.192.Supp.141.14","article-title":"Heterologous prime-boost with Ad35\/AERAS-402 and MVA85A elicits potent CD8+ T cell immune responses in a phase I clinical trial (VAC7P.969)","volume":"192","author":"Hokey","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.ijid.2016.10.018_bib0290","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Luabeya","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0295","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.vaccine.2016.01.062","article-title":"A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults","volume":"34","author":"Minhinnick","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0300","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine M72\/AS01E in adolescents in a TB endemic setting","volume":"33","author":"Penn-Nicholson","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0305","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(14)70845-X","article-title":"Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial","volume":"14","author":"Satti","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2016.10.018_bib0310","doi-asserted-by":"crossref","first-page":"205ra134","DOI":"10.1126\/scitranslmed.3006843","article-title":"A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity","volume":"5","author":"Smaill","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2016.10.018_bib0315","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1016\/j.vaccine.2015.10.017","article-title":"Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A","volume":"33","author":"Stylianou","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0320","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1016\/j.vaccine.2010.02.094","article-title":"Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers","volume":"28","author":"van Dissel","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0325","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1016\/j.vaccine.2014.10.036","article-title":"A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human","volume":"32","author":"van Dissel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0330","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2016.10.018_bib0335","doi-asserted-by":"crossref","first-page":"53ra74","DOI":"10.1126\/scitranslmed.3001094","article-title":"A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis","volume":"2","author":"Bertholet","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2016.10.018_bib0340","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.vaccine.2012.12.053","article-title":"Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial","volume":"31","author":"Grode","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0345","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ijid.2016.10.018_bib0350","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.micinf.2016.03.005","article-title":"Post-exposure vaccination with the vaccine candidate bacillus Calmette\u2013Gu\u00e9rin Delta ureC::hly induces superior protection in a mouse model of subclinical tuberculosis","volume":"18","author":"Gengenbacher","year":"2016","journal-title":"Microbes Infect"},{"key":"10.1016\/j.ijid.2016.10.018_bib0355","first-page":"155","article-title":"Protective inoculation against human tuberculosis with heat-killed tubercle bacilli","volume":"29","author":"Opie","year":"1939","journal-title":"Am J Hyg"},{"key":"10.1016\/j.ijid.2016.10.018_bib0360","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1164\/arrd.1959.80.5.676","article-title":"Vaccination against tuberculosis with nonliving vaccines. I. The problem and its historical background","volume":"80","author":"Weiss","year":"1959","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.ijid.2016.10.018_bib0365","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1097\/QAD.0b013e3283350f1b","article-title":"DarDar Study Group. Prevention of tuberculosis in bacille Calmette\u2013Gu\u00e9rin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine","volume":"24","author":"von Reyn","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.ijid.2016.10.018_bib0370","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3892\/br.2016.624","article-title":"Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"4","author":"Weng","year":"2016","journal-title":"Biomed Rep"},{"key":"10.1016\/j.ijid.2016.10.018_bib0375","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/infdis\/jiw228","article-title":"Vaccination against tuberculosis with whole-cell mycobacterial vaccines","volume":"214","author":"Scriba","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2016.10.018_bib0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005667","article-title":"CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease","volume":"12","author":"Sakai","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijid.2016.10.018_bib0385","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/infdis\/jiv447","article-title":"Excessive cytolytic responses predict tuberculosis relapse after apparently successful treatment","volume":"213","author":"Cliff","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijid.2016.10.018_bib0390","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.14971","article-title":"Addition of Mycobacterium indicus pranii (MIP) vaccine as an immunotherapeutic with standard chemotherapy in borderline leprosy: a double blind study to assess clinical improvement (A preliminary report)","author":"Kamal","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijid.2016.10.018_bib0395","doi-asserted-by":"crossref","first-page":"e89612","DOI":"10.1371\/journal.pone.0089612","article-title":"Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection","volume":"9","author":"Nell","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ijid.2016.10.018_bib0400","doi-asserted-by":"crossref","first-page":"g4643","DOI":"10.1136\/bmj.g4643","article-title":"Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis","volume":"349","author":"Roy","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ijid.2016.10.018_bib0405","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/thoraxjnl-2014-205688","article-title":"The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland","volume":"69","author":"Michelsen","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ijid.2016.10.018_bib0410","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S0140-6736(05)67534-4","article-title":"Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study","volume":"366","author":"Soysal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2016.10.018_bib0415","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1016\/j.vaccine.2015.03.061","article-title":"Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis: Conference proceedings: National Institute of Allergy and Infectious Diseases, Rockville, Maryland USA, November 7, 2014","volume":"33","author":"Vaccine Prevention of Sustained Mycobacterium tuberculosis Infection Summary Group","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2016.10.018_bib0420","doi-asserted-by":"crossref","first-page":"276fs8","DOI":"10.1126\/scitranslmed.aaa4730","article-title":"Tuberculosis vaccines: time for a global strategy","volume":"7","author":"Kaufmann","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijid.2016.10.018_bib0425","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/joim.12212","article-title":"Recent advances towards tuberculosis control: vaccines and biomarkers","volume":"275","author":"Weiner","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.ijid.2016.10.018_bib0430","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/S0140-6736(15)01316-1","article-title":"Teams AaG-C. A blood RNA signature for tuberculosis disease risk: a prospective cohort study","volume":"387","author":"Zak","year":"2016","journal-title":"Lancet"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971216312024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971216312024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T14:38:21Z","timestamp":1692542301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971216312024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":43,"alternative-id":["S1201971216312024"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2016.10.018","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel approaches to tuberculosis vaccine development","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2016.10.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}